Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Huge moves are being made near MNKD's all time low's. This stock has become toxic to shorts.
I think of MNKD right now, as a wild animal backed into a corner. The options are limited but whatever option it choses it has to bring with a vengeance to survive. Fight or flight is out the door, now it is just fight (so to speak).
Please list disadvantages as there are always at least some. Suggestion: take apple cider vinegar and cinnamon on a regular basis with lots of water.
You just had to bring up pbyi... i was on the fence buying puma @ $29 or Mnkd at .98, i chose mnkd. Sold it at 1.62 so i guess i'm happy.
USA Today- "Could your next prescription come from Amazon?"
https://www.usatoday.com/story/tech/news/2017/05/19/amazon-online-prescription-drug-sales-mail-order-online/101837676/
Would you claim the FDA has the best interests in mind of the general public? Who gets to vote because i would love to be on that panel. Anyway, tomorrow mnkd closes 5% above yesterday;s close if not a lot more based on the "Amazon affect."
Fellas, I need some help deciphering this. Follow the links.
http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2016/02/WC500201230.pdf
http://www.granzer.biz/about_founder.html
What Amazon could do to the business of selling prescription drugs
Source: Washington Post
Link:
https://www.washingtonpost.com/news/wonk/wp/2017/05/17/what-amazon-could-do-to-the-business-of-selling-prescription-drugs/?utm_term=.a2526a18d941
Iggy, its just human nature/psychological, you list the most important first. Thats why Amgen got bumped UP over Merck and Astra on Advaxis website (because what AMGN brought to the table). IMO, it is still important Dan mentioned MRK first.
I have been watching MNKD's progress for years. I almost pulled the trigger last year, thank God i did not. BUT in a convenience driven society... where is this product going? With proper marketing mixed with ease of use (compared to the pain of pricking ones self) app driven data...rising diabetes diagnosis worldwide. Afrezza is not going to just disappear. It may languish here for a bit but most importantly we are talking about #1 diabetes, #2 convenience (soon paired with app driven data), #3 an already approved product. GLTA.
I also agree about who is mentioned first in orders of importance. The fact that he mentioned merck first is a tell, imo.
This is an approved product treating diabetes and some think it will just disappear? Dont think so. Buyout or merger is imminent, imo.
Nice first post Uhitit1. Sorry if I am skeptical.
mp, thank you!! I found this company when doing research about my Dad's illness which put him into the hospital for 2 weeks ( Bursitis which turned into MRSA, possibly the other way around ). Encouraging data to answer your "I don't know" section if you get bored. Thanks again, very helpful.
Mpreorder, I recently have taken a position in Nabriva (NBRV). I would greatly appreciate your thoughts, given your profession. Better yet,would be a private reply.
Do you notice how the gap in share price between ADRO and ADXS has been closing lately? I surmise we surpass Adro shp within months, with EU approval. God willing we choose not to go alone and get a major BP to back us!
Dan has been acting mighty confident lately and mix that with massive hiring over the last 2 years (considering percentage of growth of staff). This is not all telling but better then then the latter.
On the other hand... I have shaken the hands of the largest cattle producers in the world, doesnt mean we sit at the same table...
Christopher Duke
Senior Vice President and Chief Operating Officer
Mr. Duke joined Advaxis in October 2016 as Senior Vice President and Chief Operating Officer. He brings more than 20 years of life sciences experience to the Advaxis team, and is responsible for leading operations with a focus on overseeing clinical development programs and managing early commercial planning activities. Prior to joining Advaxis, Mr. Duke was Vice President, Global Commercial Operations at Amicus Therapeutics, Inc. where he played a lead role in the build out of the international business to support the successful launch of Galafold™ (migalastat), which was granted full approval by the European Commission in 2016. Mr. Duke was one of the first employees at Amicus and held several leadership roles in program/alliance management, medical affairs and commercial planning for 10 years.
Mr. Duke also served as Executive Director, International Commercial Operations for NPS Pharma where he led several strategic business planning initiatives and helped to establish NPS International to support the ex-US commercialization of Revestive® (teduglutide) and Natpar® (rhPTH[1-84]). He received his MBA from the Wharton School, University of Pennsylvania, his MPH from the University of Medicine and Dentistry of New Jersey, and a Bachelor of Science in Chemical Engineering from Rutgers University.
He has ties to another fairly new hire but i am a couple of woodford reserve's too many to look that up. Solid hire from the get go and impressive background, imo.
If you need a reminder what a short squeeze looks like check out MNKD. I was fortunate to get in on Monday on a fluke buy.
Dan is definitely acting "boss" lately. If my tea leaves are all facing the right direction its because he is confident about the success of Advaxis. Minus the share price things lately have been looking REALLY good.
Thank you. Pretty cool Dan is directly behind Trump.
Can someone please post the link about Dan going to the white house, couldnt find it. (Cant believe i actually just wrote that, lolol)
Up 20% pre-market.
Ask him yourself instead of asking fellow shareholders.
Strong day, moderate close which means little. Tomorrow will tell all
Just glad to be in at .98!
And the rest of us just get lucky....? or are smart?....blessed? Or my favorite, all the above.
GLTA,
tex
Side note terry...an ounce of prevention is worth a pond of cure.
Incyte collab is no more. No PR about it, that i can remember, just gone.
Do we have another NEW Investor Relation's person?...or is this old news?
Investor Relations
Advaxis, Inc.
Noelle Heber
Sr. Director, Corporate Communications and Government Affairs
I have to admit the timing of this very generous gift, hits below the belt. DO just had his holdings increased by almost 50% while Bonstein and Petit by 33%. They better flippin earn it!!!!
Terry did you ever read any of Justice and Equality's posts from the YMB? I remember him describing our delivery and mechanism as being "romantic." I probably won't ever forget that descriptic word being applied to our tech.
If employees are happy and well taken care of at their place of employment,fbg, they create a higher quality "product/company/service/experience, etc." A good friend of mine spent $70,000 in classes so he could be taught these principals. Since his implementation, his business has exploded. I helped my previous boss build a $2.5 million business (just out of college) into a $30+ million corporation in 5 years using these principals. I am tired of listening to your bashing. Its the same over and over and it reminds me of legrande from the YMB. I am royally pissed at the condition of our current shp and we got it, you blame Dan but enough is enough. Seriously fbg, i have been contemplating on putting you on ignore for some time now especially since you refuse to voice your opinion to IR or Dan himself (James doesn't seem to have any problems doing so nor have I over the years). We are shareholders on this MB and if you want to spread doubt or fear then you are doing a fine job. I prefer constructive criticism, when applicable but i miss the old FBG....sigh :(
james, I would love to see approval before 2018 but I think Feb-May, 2018 is more likely. We have an "up to" 150 active day scientific evaluation assessment after MAA submission. The CHMP must then issue their "scientific opinion" (which no timeframe is given). After which the opinion for the go ahead (assuming its positive) is THEN given to the European Commission which in turn they have within 67 days of receipt of CHMP's decision to issue MAA. From what i can tell there is much dialogue back and forth before the submission of the MAA application which is why Advaxis has not submitted the application....say... yesterday. I do understand the optimism and the days previously mentioned are, and I quote "Up to" and "Within" so....maybe? BUT, that is 217 days at the latest PLUS however long the CHMP takes to make their decision, if we filed the application tomorrow. Per ADXS, they do not plan on filing till early 2nd Half 2017.
After diving into the EMA process, I would say that earlier than expected approval is highly doubtful. Standard procedure is just that. Why would special treatment be granted to us? A European partnership is the key, imo. Unless somehow we did not declare (or is unknown) that some of our employed are oversees? Just babble rubbish from a guy that raises animals and plants seeds for a living.
Could be ADXS and ADRO are being tested on who should have the higher SHP and later test their MC... call it their inflection point.
Terry, i read one of your earlier posts where you mentioned AXAL is soon to be obsolete (not verbatim). Can you please elaborate on why you think such to be true and who is the front runner to compete with our data, given we somewhat kicked butt vs SOC. Also, I would like to mention i am no "Tax Farmer." I had to google that one as i have never heard of it before...only 1 letter off, so kudos on the analogy.
Is that what your tea leaves are saying? I have seen many predictions of what is to come regarding adxs shp. A small tip, the vast majority are wrong but gltu.